Skip to main content
Top

13-03-2024 | Myocarditis | Research

Analysis of Cytokine Profiles in Pediatric Myocarditis Multicenter Study

Authors: Yoji Nomura, Takanori Suzuki, Katsuyuki Kunida, Hidetoshi Uchida, Ryoichi Ito, Yasunori Oshima, Machiko Kito, Yuki Imai, Satoru Kawai, Kei Kozawa, Kazuyoshi Saito, Tadayoshi Hata, Junichiro Yoshimoto, Tetsushi Yoshikawa, Kazushi Yasuda

Published in: Pediatric Cardiology

Login to get access

Abstract

Acute myocarditis (AM) is an inflammatory disease of the heart muscle that can progress to fulminant myocarditis (FM), a severe and life-threatening condition. The cytokine profile of myocarditis in children, especially in relation to fulminant myocarditis, is not well understood. This study aims to evaluate the cytokine profiles of acute and fulminant myocarditis in children. Pediatric patients diagnosed with myocarditis were included in the study. Cytokine levels were measured using a multiplexed fluorescent bead-based immunoassay. Statistical analysis was performed to compare patient characteristics and cytokine levels between FM, AM, and healthy control (HC) groups. Principal component analysis (PCA) was applied to cytokine groups that were independent among the FM, AM, and HC groups. The study included 22 patients with FM and 14 with AM patients. We identified four cytokines that were significantly higher in the FM group compared to the AM group: IL1-RA (p = 0.002), IL-8 (p = 0.005), IL-10 (p = 0.011), and IL-15 (p = 0.005). IL-4 was significantly higher in the AM group compared to FM and HC groups (p = 0.006 and 0.0015). PDGF-AA, and VEGF-A were significantly lower in the FM group than in the AM group (p = 0.013 and <0.001). Similar results were obtained in PCA. Cytokine profiles might be used to differentiate pediatric FM from AM, stratify severity, and predict prognosis. The targeted therapy that works individual cytokines might provide a potential treatment for reducing the onset of the FM and calming the condition, and further studies are needed.
Appendix
Available only for authorised users
Literature
2.
go back to reference Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB et al (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34(33):2636–2648CrossRefPubMed Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB et al (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34(33):2636–2648CrossRefPubMed
3.
go back to reference Amioka N, Nakamura K, Kimura T, Ohta-Ogo K, Tanaka T, Toji T et al (2021) Pathological and clinical effects of interleukin-6 on human myocarditis. J Cardiol 78(2):157–165CrossRefPubMed Amioka N, Nakamura K, Kimura T, Ohta-Ogo K, Tanaka T, Toji T et al (2021) Pathological and clinical effects of interleukin-6 on human myocarditis. J Cardiol 78(2):157–165CrossRefPubMed
4.
go back to reference Nishii M, Inomata T, Takehana H, Takeuchi I, Nakano H, Koitabashi T et al (2004) Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis. J Am Coll Cardiol 44(6):1292–1297CrossRefPubMed Nishii M, Inomata T, Takehana H, Takeuchi I, Nakano H, Koitabashi T et al (2004) Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis. J Am Coll Cardiol 44(6):1292–1297CrossRefPubMed
9.
go back to reference Yokoe I, Kobayashi H, Kobayashi Y, Giles JT, Yoneyama K, Kitamura N et al (2018) Impact of tocilizumab on N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis without cardiac symptoms. Scand J Rheumatol 47(5):364–370CrossRefPubMed Yokoe I, Kobayashi H, Kobayashi Y, Giles JT, Yoneyama K, Kitamura N et al (2018) Impact of tocilizumab on N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis without cardiac symptoms. Scand J Rheumatol 47(5):364–370CrossRefPubMed
10.
go back to reference Kleveland O, Kunszt G, Bratlie M, Ueland T, Broch K, Holte E et al (2016) Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J 37(30):2406–2413CrossRefPubMed Kleveland O, Kunszt G, Bratlie M, Ueland T, Broch K, Holte E et al (2016) Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J 37(30):2406–2413CrossRefPubMed
11.
go back to reference Kleveland O, Ueland T, Kunszt G, Bratlie M, Yndestad A, Broch K et al (2018) Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction. Int J Cardiol 271:1–7CrossRefPubMed Kleveland O, Ueland T, Kunszt G, Bratlie M, Yndestad A, Broch K et al (2018) Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction. Int J Cardiol 271:1–7CrossRefPubMed
13.
go back to reference Hossein Heydari A, Ghaffari S, Khani Z, Heydari S, Eskandari Z, Esmaeil HM (2023) MiR-21, and Tocilizumab interactions improve COVID-19 myocarditis outcomes. Ther Adv Cardiovasc Dis 17:17539447231182548CrossRefPubMedPubMedCentral Hossein Heydari A, Ghaffari S, Khani Z, Heydari S, Eskandari Z, Esmaeil HM (2023) MiR-21, and Tocilizumab interactions improve COVID-19 myocarditis outcomes. Ther Adv Cardiovasc Dis 17:17539447231182548CrossRefPubMedPubMedCentral
14.
go back to reference Niño-Taravilla C, Espinosa-Vielma YP, Otaola-Arca H, Poli-Harlowe C, Tapia LI, Ortiz-Fritz P (2020) Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 treated with tocilizumab. Pediatr Rep 12(3):142–148CrossRefPubMedPubMedCentral Niño-Taravilla C, Espinosa-Vielma YP, Otaola-Arca H, Poli-Harlowe C, Tapia LI, Ortiz-Fritz P (2020) Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 treated with tocilizumab. Pediatr Rep 12(3):142–148CrossRefPubMedPubMedCentral
16.
go back to reference Lim BK, Choe SC, Shin JO, Ho SH, Kim JM, Yu SS et al (2002) Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis. Circulation 105(11):1278–1281CrossRefPubMed Lim BK, Choe SC, Shin JO, Ho SH, Kim JM, Yu SS et al (2002) Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis. Circulation 105(11):1278–1281CrossRefPubMed
17.
go back to reference Nakano A, Matsumori A, Kawamoto S, Tahara H, Yamato E, Sasayama S et al (2001) Cytokine gene therapy for myocarditis by in vivo electroporation. Hum Gene Ther 12(10):1289–1297CrossRefPubMed Nakano A, Matsumori A, Kawamoto S, Tahara H, Yamato E, Sasayama S et al (2001) Cytokine gene therapy for myocarditis by in vivo electroporation. Hum Gene Ther 12(10):1289–1297CrossRefPubMed
18.
go back to reference Colantuoni M, Jofra Hernandez R, Pettinato E, Basso-Ricci L, Magnani L, Andolfi G et al (2023) Constitutive IL-1RA production by modified immune cells protects against IL-1-mediated inflammatory disorders. Sci Transl Med 15(698):eade3856CrossRefPubMed Colantuoni M, Jofra Hernandez R, Pettinato E, Basso-Ricci L, Magnani L, Andolfi G et al (2023) Constitutive IL-1RA production by modified immune cells protects against IL-1-mediated inflammatory disorders. Sci Transl Med 15(698):eade3856CrossRefPubMed
19.
go back to reference Cavalli G, Pappalardo F, Mangieri A, Dinarello CA, Dagna L, Tresoldi M (2016) Treating life-threatening myocarditis by blocking interleukin-1. Crit Care Med 44(8):e751-754CrossRefPubMed Cavalli G, Pappalardo F, Mangieri A, Dinarello CA, Dagna L, Tresoldi M (2016) Treating life-threatening myocarditis by blocking interleukin-1. Crit Care Med 44(8):e751-754CrossRefPubMed
20.
go back to reference Trpkov C, MacMullan P, Feuchter P, Kachra R, Heydari B, Merchant N et al (2021) Rapid response to cytokine storm inhibition using anakinra in a patient with COVID-19 myocarditis. CJC Open 3(2):210–213CrossRefPubMed Trpkov C, MacMullan P, Feuchter P, Kachra R, Heydari B, Merchant N et al (2021) Rapid response to cytokine storm inhibition using anakinra in a patient with COVID-19 myocarditis. CJC Open 3(2):210–213CrossRefPubMed
21.
go back to reference Maunier L, Charbel R, Lambert V, Tissières P, CLOVIS study group (2022) Anakinra in pediatric acute fulminant myocarditis. Ann Intensive Care 12(1):80CrossRefPubMedPubMedCentral Maunier L, Charbel R, Lambert V, Tissières P, CLOVIS study group (2022) Anakinra in pediatric acute fulminant myocarditis. Ann Intensive Care 12(1):80CrossRefPubMedPubMedCentral
22.
go back to reference Kaya Z, Dohmen KM, Wang Y, Schlichting J, Afanasyeva M, Leuschner F et al (2002) Cutting edge: a critical role for IL-10 in induction of nasal tolerance in experimental autoimmune myocarditis. J Immunol 168(4):1552–1556CrossRefPubMed Kaya Z, Dohmen KM, Wang Y, Schlichting J, Afanasyeva M, Leuschner F et al (2002) Cutting edge: a critical role for IL-10 in induction of nasal tolerance in experimental autoimmune myocarditis. J Immunol 168(4):1552–1556CrossRefPubMed
23.
go back to reference Wang ZH, Liao YH, Yuan J, Jin XJ, Yu M, Chen RZ et al (2020) Continued elevation of plasma IL-4 and IL-17 predicts the progression from VMC to DCM. Dis Markers 2020:9385472CrossRefPubMedPubMedCentral Wang ZH, Liao YH, Yuan J, Jin XJ, Yu M, Chen RZ et al (2020) Continued elevation of plasma IL-4 and IL-17 predicts the progression from VMC to DCM. Dis Markers 2020:9385472CrossRefPubMedPubMedCentral
24.
go back to reference Diny NL, Baldeviano GC, Talor MV, Barin JG, Ong S, Bedja D et al (2017) Eosinophil-derived IL-4 drives progression of myocarditis to inflammatory dilated cardiomyopathy. J Exp Med 214(4):943–957CrossRefPubMedPubMedCentral Diny NL, Baldeviano GC, Talor MV, Barin JG, Ong S, Bedja D et al (2017) Eosinophil-derived IL-4 drives progression of myocarditis to inflammatory dilated cardiomyopathy. J Exp Med 214(4):943–957CrossRefPubMedPubMedCentral
25.
go back to reference Taimeh Z, Loughran J, Birks EJ, Bolli R (2013) Vascular endothelial growth factor in heart failure. Nat Rev Cardiol 10(9):519–530CrossRefPubMed Taimeh Z, Loughran J, Birks EJ, Bolli R (2013) Vascular endothelial growth factor in heart failure. Nat Rev Cardiol 10(9):519–530CrossRefPubMed
26.
go back to reference Medamana J, Clark RA, Butler J (2017) Platelet-derived growth factor in heart failure. Handb Exp Pharmacol 243:355–369CrossRefPubMed Medamana J, Clark RA, Butler J (2017) Platelet-derived growth factor in heart failure. Handb Exp Pharmacol 243:355–369CrossRefPubMed
Metadata
Title
Analysis of Cytokine Profiles in Pediatric Myocarditis Multicenter Study
Authors
Yoji Nomura
Takanori Suzuki
Katsuyuki Kunida
Hidetoshi Uchida
Ryoichi Ito
Yasunori Oshima
Machiko Kito
Yuki Imai
Satoru Kawai
Kei Kozawa
Kazuyoshi Saito
Tadayoshi Hata
Junichiro Yoshimoto
Tetsushi Yoshikawa
Kazushi Yasuda
Publication date
13-03-2024
Publisher
Springer US
Published in
Pediatric Cardiology
Print ISSN: 0172-0643
Electronic ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-024-03452-6